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 Crohn ’ s disease (CD) and ulcerative colitis (UC) 
are the two key forms of infl ammatory bowel 
diseases (IBDs) in humans ( 1 – 3 ). Growing evi-
dence indicates a central role of a genetically de-
termined dysregulation of the mucosal immune 
response toward the resident bacterial fl ora in 
the pathogenesis of human IBD ( 4 ). This patho-
logical immune response is characterized by an 
accumulation of antigen-presenting cells and T 
cells that represent the vast majority of activated 
mononuclear cells infi ltrating the gut ( 5 – 8 ). 
 The diff erentiation and activation of CD4 + 
T cells in the lamina propria play a major role in 
the pathogenesis of IBD ( 9 ). Whereas CD is as-
sociated with increased production of Th1-like 
cytokines such as IFN-  and TNF, the cytokine 
profi le in chronic UC is characterized by the 
 increased production of several Th2 cytokines, 
such as IL-5, -6,  and -13 ( 7, 8, 10, 11 ). Interest-
ingly, both Th1- and Th2-type cytokines have 
been shown to play an important pathogenic 
role in various animal models of IBD, suggesting 
that both T helper subsets can induce chronic 
intestinal infl ammation in vivo ( 11, 12 ). This 
pathogenic function of Th1 and Th2 cells can be 
counteracted by immunosuppressive cytokines 
such as IL-10 and TGF-  , which are produced 
by regulatory T cells and Th1 cells ( 11 – 15 ). 
 T lymphocytes transit through sequential 
stages of cytokine activation, commitment, silenc-
ing, and physical stabilization during polarization 
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 The nuclear factor of activated T cells (NFAT) family of transcription factors controls 
calcium signaling in T lymphocytes. In this study, we have identifi ed a crucial regulatory 
role of the transcription factor NFATc2 in T cell – dependent experimental colitis. Similar to 
ulcerative colitis in humans, the expression of NFATc2 was up-regulated in oxazolone-
induced chronic intestinal infl ammation. Furthermore, NFATc2 defi ciency suppressed colitis 
induced by oxazolone administration. This fi nding was associated with enhanced T cell 
apoptosis in the lamina propria and strikingly reduced production of IL-6, -13, and -17 by 
mucosal T lymphocytes. Further studies using knockout mice showed that IL-6, rather than 
IL-23 and -17, are essential for oxazolone colitis induction. Administration of hyper-IL-6 
blocked the protective effects of NFATc2 defi ciency in experimental colitis, suggesting 
that IL-6 signal transduction plays a major pathogenic role in vivo. Finally, adoptive trans-
fer of IL-6 and wild-type T cells demonstrated that oxazolone colitis is critically dependent 
on IL-6 production by T cells. Collectively, these results defi ne a unique regulatory role for 
NFATc2 in colitis by controlling mucosal T cell activation in an IL-6 – dependent manner. 
NFATc2 in T cells thus emerges as a potentially new therapeutic target for infl ammatory 
bowel diseases. 
© 2008 Weigmann et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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been shown to control Th2 cytokine production, STAT-1, 
STAT-4, and T-bet are associated with signaling events in Th1 
cells and play a key role in Th1-specifi c cytokine production 
in peripheral T cells ( 16, 17 ). In the mucosal immune system, 
several studies have suggested important roles for STAT-4 and 
T-bet in Th1 cell eff ector functions in the gut in experimental 
colitis and CD ( 9, 18, 19 ). However, the functional role of 
other T cell transcription factors such as nuclear factor of acti-
vated T cells (NFAT) in IBD is poorly understood. 
 The NFAT family of transcription factors consists of 
fi ve members: NFATc1 (also known as NFATc or NFAT2), 
NFATc2 (NFATp or NFAT1), NFATc3 (NFATx or NFAT4), 
NFATc4 (NFAT3), and NFAT5 (TonEBP or OREBP) ( 20 – 23 ). 
All NFAT proteins have a highly conserved DNA-binding 
domain that is structurally related to the DNA-binding 
domain of the REL family of transcription factors ( 23, 24 ). 
This REL-homology region (RHR) is the unifying char-
acteristic of NFAT proteins and confers a common DNA-
binding specifi city. 
 NFAT proteins seem to play a pivotal role in the activa-
tion and diff erentiation of T lymphocytes and are activated by 
calcium signaling ( 22 – 25 ). In fact, calcium-bound calmodulin 
activates the calcineurin phosphatase complex, which dephos-
phorylates NFATc1 and causes its import into the nucleus, 
where NFATc1 and its nuclear partner, NFATn, cooperatively 
bind to DNA. NFATc1 complexes act as  “ coincidence de-
tectors ” and allow the integration of multiple signaling path-
ways at the level of DNA binding. In addition to NFATc1, 
NFATc2 is constitutively expressed in T cells and controls T 
cell activation and survival ( 22, 24-26 ). Consistently, NFATc2 
KO mice developed a hyperproliferative syndrome with in-
creased numbers of peripheral lymphocytes caused by defects 
in activation-induced cell death and reduced expression of sev-
eral proapoptotic genes, such as CD95L and TNF ( 27 – 29 ). 
NFATc2-defi cient mice also showed alterations in T cell cyto-
kine production. Whereas NFATc2-defi cient splenic T cells 
displayed reduced early IL-4 production, increased levels of 
IL-4 were found at later time points during Th2 development, 
suggesting that NFATc2 is important for cytokine production 
by peripheral T cells ( 27, 28 ). 
 In contrast to peripheral T cells, the function of NFATc2 
in mucosal T cells remains largely unknown. Therefore, the 
aim of this study was to analyze the role of NFATc2 signal 
transduction in intestinal infl ammation. A signifi cantly higher 
expression of NFATc2 was found in UC tissues compared 
with control samples. Furthermore, NFATc2 was found to 
play a pivotal regulatory role in T cell – dependent experimen-
tal colitis by controlling IL-6 – dependent T cell activation. 
 RESULTS 
 Enhanced expression of NFATc2 in patients with IBDs 
 The NFAT plays a fundamental role in controlling calcium-
dependent T cell activation ( 23, 30-32 ). As T cells have 
been suggested to play a major role in patients with IBDs, we 
analyzed expression of NFATc2 by immunohistochemistry. 
Accordingly, colonic cryosections from IBD patients were 
into eff ector subsets, a process that is tightly controlled by reg-
ulatory transcriptional events ( 3, 16, 17 ). Although transcrip-
tion factors such as STAT-6, GATA-3, c-Maf and JunB have 
 Figure 1.  Enhanced expression of NFATc2 transcription factors in 
patients with IBDs compared with control patients. (A) Immunohisto-
chemistry for NFATc2 expression. Colon cross sections were incubated with 
NFATc2-specifi c antibodies and analyzed by microscopy. An increased ex-
pression of NFATc2 was observed in sections from UC and CD patients 
compared with control patients. Representative stainings from 5 to 10 
patients per group are shown. (B) Quantitative analysis of positive cells 
revealed a signifi cantly increased number of NFATc2-positive cells in IBD 
patients compared with control patients. Data represent mean values  ± the 
SD per high power fi eld. *, P  < 0.05. (C) Detection of NFATc2-expressing 
T cells in the lamina propria of patients with IBDs. Samples from CD, UC, and 
control patients were stained with anti-NFATc2 and anti-CD3 antibodies, 
followed by confocal laser microscopy. Nuclei were stained with DAPI. Rep-
resentative pictures are shown. Staining with an isotype control antibody 
served as negative control. CD3/NFATc2 double-positive, yellowish cells 
were seen in the lamina propria in CD and UC. Bars: (A) 80  μ m; (C) 30  μ m. 
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 T lymphocytes are key eff ector cells in the pathogenesis 
of IBD and produce several proinfl ammatory cytokines that 
contribute to tissue destruction in IBD ( 4, 12 ). To deter-
mine whether T lymphocytes in IBD express NFAT proteins, 
stained with NFATc2-specifi c antibodies. As shown in  Fig. 1 
(A and B) , NFATc2-positive cells were found in the lamina 
propria of control patients, and the number of these cells was 
signifi cantly increased in patients with IBD. 
 Figure 2.  A regulatory role of NFATc2 in oxazolone-induced experimental colitis.  (A) Enhanced expression of the NFATc2 transcription factor in 
oxazolone-induced colitis. Colonic cryosections from WT and NFATc2 KO mice were incubated with anti-NFATc2 antibodies followed by tyramide signal 
amplifi cation. An increased expression of NFATc2 was observed in colonic tissue from WT mice with oxazolone colitis (WT oxa) as compared with WT un-
challenged mice. Colonic tissue from NFATc2 KO mice (NFATc2 oxa) served as negative control and did not reveal any specifi c staining as expected. 
(B) Oxazolone colitis was induced by sensitizing mice with oxazolone, followed by intrarectal administration of the hapten reagent after 1 wk. The body 
weight of the mice was monitored after oxazolone rechallenge at the indicated time points. Mean values  ± the SEM from two representative experiments 
out of six are shown. The average weight of the mice at the beginning of the experiments was 22.9 g (WT group) and 22.5 g (NFATc2 KO group), respec-
tively. For this experiment, 6 WT and 7 NFATc2 KO mice were used. (C) Histological sections (left) of colonic infl ammation in WT or NFATc2-defi cient mice 
upon oxazolone administration. Signs of infl ammation such as goblet cell depletion, ulcers, and accumulation of mononuclear cells were noted in WT 
mice, whereas NFATc2 KO mice showed little or no evidence of colitis. Quantitative histopathologic assessment of colitis activity (right) showed a signifi -
cant (*P  < 0.05) protection from infl ammation and tissue injury in NFATc2 KO mice compared with WT mice. Data represent mean values  ± the SEM from 
one representative experiment out of six. (D) High-resolution miniendoscopic analysis (left) of the colon of NFATc2 KO and WT mice in oxazolone colitis. 
Marked erosions and ulcers were seen in the WT group, whereas an almost normal colon architecture was noted in NFATc2-defi cient mice. Quantitative 
endoscopic analysis (right) of infl ammation (MEICS score) in WT and NFATc2 KO mice in oxazolone colitis was done at day 2 after administration of oxa-
zolone. A signifi cantly (P  < 0.05) lower endoscopic score was observed in NFATc2-defi cient mice compared with WT mice. (E) Adoptive T cell transfer from 
WT and NFATc2-defi cient mice in SCID mice. CD4 + T cells were transferred into CB-17/SCID mice, followed by oxazolone sensitization and intrarectal oxa-
zolone administration. The body weight of reconstituted mice was analyzed at indicated time points. Mean values  ± SEM from one representative experi-
ment out of three are shown. Whereas mice reconstituted with WT T cells showed a marked weight loss, mice given NFATc2-defi cient T cells were 
protected from colitis and gained weight. For this experiment fi ve SCID mice in each group were used. Bars: (A) 80  μ m; (C) 100  μ m. 
2102 NFACTC2 IN COLITIS | Weigmann et al. 
 Figure 3.  Augmented T cell apoptosis in the colon of NFATc2-defi cient mice in oxazolone-induced colitis.  (A) Cryosections of colonic tissue 
from WT and NFATc2-defi cient mice in oxazolone-induced colitis were made, and apoptotic cells were stained using the TUNEL reaction. Staining of the 
nuclei was done with DAPI. Representative stainings from WT and NFATc2 KO mice, as well as negative and positive control stainings are shown (left). 
(right) Quantitative analysis of apoptotic cells in 10 randomly selected high power fi elds per sample. Data represent mean values  ± the SD. A signifi cantly 
(P  < 0.05) higher number of apoptotic cells was observed in colonic tissue from NFATc2-defi cient mice in oxazolone-induced colitis compared with WT 
control mice. Bar, 100  μ m. (B) Double staining analysis of colonic tissue from WT and NFATc2-defi cient mice in oxazolone-induced colitis using TUNEL 
assays and anti-CD3 antibodies (left). Cryosections were analyzed by confocal laser microscopy for apoptotic T cells, and representative pictures are 
shown (right). A higher number of apoptotic/CD3 double-positive cells (FITC TUNEL staining; Cy3 stained CD3) was observed in NFATc2 mice compared 
with WT mice. (C) An increased number of apoptotic LPMCs in NFATc2-defi cient mice upon administration of oxazolone. LPMCs from WT and NFATc2-
defi cient mice were isolated and stained with 7-AAD and anti – Annexin V antibodies for FACS analysis. In comparison to WT cells, LPMCs from NFATc2-
defi cient mice showed an increased number of apoptotic cells in oxazolone-induced colitis. Representative FACS analyses of different groups of mice for 
annexin V are shown. Quantitative analysis of apoptotic LPMCs was performed in three independent experiments (bottom). Data represent mean values  ± 
the SD. There was a signifi cant (*, P  < 0.05) increase of apoptotic LPMCs in NFATc2-defi cient mice as compared with WT control mice. (D) Increased num-
ber of apoptotic lamina propria CD4 + T cells in NFATc2-defi cient mice in oxazolone-induced colitis. LPMCs from WT and NFATc2-defi cient mice were 
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prepared, and CD4 + T cells were isolated by using the MACS-System. Cells were stained with 7-AAD and anti – Annexin V antibodies for subsequent analy-
sis (top). Lamina propria T cells from NFATc2 KO mice showed an increased percentage of apoptotic cells in colitis compared with WT mice. Quantitative 
analysis of apoptotic CD4 T cells was performed in two experiments (bottom). Data represent mean values  ± the SD. There was a signifi cant (*, P  < 0.05) 
increase of apoptotic lamina propria T cells in NFATc2-defi cient mice compared with WT control mice. 
 
double staining for CD3 and NFATc2 was performed ( Fig. 
1 C ). Interestingly, many T lymphocytes in the gut of IBD 
patients were positive for NFATc2, which is consistent with 
a potential regulatory role of this transcription factor in mu-
cosal T cells. 
 A key regulatory role of NFATc2 in oxazolone-
induced colitis 
 In subsequent studies, we found an induction of NFATc2 ex-
pression in WT mice with oxazolone-induced colitis as com-
pared with unchallenged mice, which is consistent with a 
potential regulatory role of NFATc2 in T cell – mediated coli-
tis ( Fig. 2 A ). To analyze the functional role of NFATc2 in 
experimental colitis, we then took advantage of genetically 
engineered mice in which the NFATc2 gene was inactivated 
by homologous recombination ( 27 ). In these studies, we de-
termined whether NFATc2-defi cient mice exhibit an altered 
susceptibility to oxazolone colitis that (similarly to UC) is 
characterized by IL-5 and -13 production by T cells ( 33, 34 ). 
It was found that NFATc2-defi cient mice were almost com-
pletely protected from oxazolone colitis. Although WT mice 
challenged with oxazolone showed a marked weight loss, no 
diarrhea and weight loss were noted in mice lacking NFATc2 
( Fig. 2 B ). Consistently, histological analysis showed signifi -
cant suppression of colitis activity in NFATc2-defi cient mice 
compared with WT mice after administration of oxazolone 
( Fig. 2 C ). Finally, endoscopic analysis revealed signifi cant 
suppression of oxazolone-induced colitis in the former as 
compared with the latter group of mice ( Fig. 2 D ). 
 To prove that the observed protective eff ect in NFATc2-
defi cient mice was caused by T lymphocytes, we next per-
formed adoptive transfer studies. Accordingly, splenic CD4 + 
T lymphocytes from WT and NFATc2-defi cient mice were 
adoptively transferred into immunodefi cient mice, followed 
by sensitization and challenge of the reconstituted mice with 
oxazolone. As shown in  Fig. 2 E , mice given WT T cells de-
veloped severe colitis with weight loss, whereas mice recon-
stituted with NFATc2-defi cient T cells were protected from 
such colitis, suggesting that NFATc2 mediates its pathogenic 
role in oxazolone colitis via its eff ects on T lymphocytes. 
 Increased apoptotic rate of NFATc2-defi cient lamina 
propria T cells in oxazolone-induced colitis 
 Because it is known that NFATc2-defi cient mice have a de-
fect in lymphocyte apoptosis ( 27, 29 ), we next assessed the 
apoptotic rate of lamina propria mononuclear cells (LPMCs) 
in oxazolone-induced colitis. Accordingly, cryosections of 
oxazolone-treated WT and NFATc2 KO mice were stained 
by TUNEL assays ( Fig. 3 A ). Surprisingly, a signifi cantly higher 
number of apoptotic cells was observed in NFATc2-defi cient 
mice as compared with WT control mice ( Fig. 3 A ). Further-
more, double staining analysis for CD3 and TUNEL ( Fig. 3 B ) 
revealed a higher number of apoptotic T cells in the former 
as compared with the latter mice, suggesting that NFATc2-
defi cient lamina propria T cells in oxazolone colitis are more 
susceptible to undergo programmed cells death than WT 
T cells. To further analyze this possibility, we analyzed freshly 
isolated T cell enriched lamina propria cells from WT and 
NFAT-defi cient mice for apoptosis by FACS analysis using 
7-amino-actinomycin D (7AAD) and anti – annexin V antibodies. 
In oxazolone-induced colitis, a signifi cantly higher rate of 
apoptotic lamina propria cells was seen in NFATc2 KO mice 
compared with WT mice ( Fig. 3 C ). Furthermore, there was a 
signifi cantly higher percentage of apoptotic T lymphocytes in 
the lamina propria of NFATc2 KO mice compared with WT 
mice in oxazolone-induced colitis ( Fig. 3 D ). Interestingly, 
NFATc2-defi cient T cells expressed lower amounts of anti-
apoptotic proteins, such as bcl-xl and bcl-2, compared with 
WT T cells in colitis (Fig. S1, available at http://www.jem
.org/cgi/content/full/jem.20072484/DC1). As NFATc2-
defi cient T cells are normally resistant to undergo apoptosis 
( 27, 29 ), our data thus suggested the possibility that external 
factors such as the cytokine milieu may cause increased muco-
sal NFATc2   /   T cell apoptosis in experimental colitis. 
 Reduced production of IL-6, -13, and -17 by NFATc2-
defi cient lamina propria T cells 
 To further test the aforementioned hypothesis, we next as-
sessed the eff ects of NFATc2 on T cell cytokine production in 
oxazolone-induced colitis. Splenic CD4 + T cells isolated from 
NFATc2-defi cient mice produced signifi cantly lower amounts 
of IFN-  , IL-6, and IL-17 but higher amounts of IL-4 than 
T cells from WT mice ( Fig. 4 A ). Furthermore, colonic LPMCs 
from NFATc2-defi cient mice produced signifi cantly lower 
amounts of IL-6, -13, and -17 in oxazolone-induced colitis 
compared with control WT cells ( Fig. 4 B ). Whereas T cell 
survival at the end of the cell cultures diff ered by only   10% 
between the groups (79% in WT vs. 70% in NFAT KO mice), 
the production of the above cytokines was reduced by  > 70% 
in the absence of NFATc2, suggesting that NFATc2 controls 
cytokine production by mucosal T cells. In contrast to IL-6, 
-13, and -17, no signifi cant changes in IL-4 production were 
noted. Furthermore, a signifi cant induction of IL-5 produc-
tion by NFATc2-defi cient cells was observed, suggesting that 
only distinct cytokines produced by T cells are reduced by 
the absence of the transcription factor NFATc2. The reduced 
IL-17 production by T cells lacking NFATc2 was remarkable, 
as both splenic and lamina propria cells from NFATc2-defi -
cient mice expressed normal or even increased amounts of the 
Th17 master transcription factor ROR-  t (unpublished data). 
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 Figure 4.  Cytokine production in oxazolone-induced colitis.  
(A) Cytokine production by splenic CD4 + T cells from WT and NFATc2-
defi cient mice in oxazolone-induced colitis. CD4 + T cells were stimulated 
with antibodies to CD3 and CD28 for 48 h, followed by analysis of culture 
supernatants using cytomix (see Materials and methods). Data represent 
mean values of four to eight mice per group. CD4 + T cells from WT mice 
produced signifi cantly (P  < 0.05) higher amounts of IFN-  , but lower 
amounts of IL-4 than NFATc2-defi cient T cells. Furthermore, a signifi -
cantly lower production of IL-6 and -17 was observed in the supernatant 
of NFATc2-defi cient CD4 + T cells in comparison to WT T cells. (B) Cytokine 
production by T cell – enriched lamina propria cells from WT and NFATc2-
defi cient mice in oxazolone-induced colitis. Lamina propria cells were 
stimulated with PMA/ionomycin, and the cell supernatant was analyzed 
using cytomix. Data represent mean values of three to six mice per group. 
T cells from WT mice produced higher amounts of IFN-  , IL-6, IL-13, and 
IL-17 when compared with cells from NFATc2-defi cient mice. At the end 
of the culture, cell survival rates differed by   10% between WT and KO 
cells only, suggesting that the marked differences in cytokine production 
under our experimental conditions are not caused by primary effects on 
T cell apoptosis. (C) IL-6 production by purifi ed CD4 + lamina propria T cells 
from WT and NFATc2-defi cient mice in oxazolone-induced colitis. LPMCs 
from WT and NFATc2-defi cient mice were prepared, and CD4 + T cells were 
isolated by using the MACS System. T cells were stimulated with PMA/
ionomycin, and supernatants were analyzed using an IL-6 – specifi c ELISA. 
Data represent mean value  ± the SD from two experiments with four 
mice per group. CD4 + lamina propria T cells from WT mice produced sig-
nifi cantly (P  < 0.05) higher amounts of IL-6 compared with cells from 
NFATc2-defi cient mice. 
 Figure 5.  Reduced capacity of IL-6 and IL-13 – defi cient mice to 
develop oxazolone-induced colitis. (A) Oxazolone colitis was induced in 
IL-13 – defi cient mice and WT mice by sensitizing mice with oxazolone, 
followed by intrarectal administration of the hapten reagent after 1 wk. 
The body weight of the mice was monitored after oxazolone rechallenge 
at indicated time points (top left). Mean values  ± SEM from one represen-
tative experiment out of two are shown. The average weight of mice at 
the beginning of the experiment was 25.8 g (WT group) and 25.8 g (IL-13 
KO group), respectively. For this experiment, 5 WT and 5 IL-13 KO mice 
were used. Endoscopic assessment of colonic infl ammation in WT (A, top 
right) or IL-13 – defi cient (A, bottom right) mice upon oxazolone adminis-
tration. In contrast to WT mice, IL-13 – defi cient mice showed little evi-
dence of colitis. Mean endoscopic scores  ± the SEM from one 
representative experiment out of two are shown (bottom left). (B) IL-6 –
 defi cient mice and WT mice were sensitized with oxazolone, followed by 
intrarectal administration of the hapten reagent after 1 wk. The body 
weight of the mice was monitored after oxazolone rechallenge at the 
indicated time points. Mean values  ± the SEM from one representative 
experiment out of three are shown (top left). The average weight of mice 
at the beginning of the experiment was 25.9 g (WT group) and 24.5 g (IL-
6 KO group), respectively. For this experiment, four WT and four IL-6 KO 
mice were used. One representative experiment out of three is shown. 
Endoscopic assessment of colonic infl ammation in WT (B, top right) or 
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IL-6 showed normal susceptibility to oxazolone-induced colitis 
comparable to WT control mice, as shown by weight curves 
( Fig. 6 A ), histopathologic criteria ( Fig. 6, B and C ), and 
miniendoscopic criteria ( Figs. 6, D and E ). In fact, hyper-
IL-6 abrogated the protection of NFATc2 KO mice in oxa-
zolone-treated mice and induced mucosal and systemic IL-6 
and -13 production as well as an increased local T cell num-
ber ( Fig. 6, F and G ) strongly suggesting that the pathogenic 
role of NFATc2 in T cell-mediated colitis is caused by regu-
lation of IL-6 production. 
 IL-6 defi ciency in T cells controls mucosal infl ammation 
in oxazolone-induced colitis 
 As the above fi ndings indicated a key role of IL-6 signaling in 
oxazolone colitis, we determined in a fi nal series of studies 
the eff ect of IL-6 defi ciency in T cells on mucosal infl amma-
tion in oxazolone-induced colitis. Accordingly, splenic CD4 + 
T cells were purifi ed from both WT and IL-6 – defi cient mice 
and adoptively transferred into immunodefi cient mice, followed 
by induction of oxazolone-induced colitis. As shown in  Fig. 7 A , 
mice given WT T cells developed severe colitis with weight 
loss, whereas mice reconstituted with IL-6 – defi cient T cells 
were protected from such colitis. Furthermore, endoscopic 
analysis showed signifi cant reduction of colitis activity in the 
latter compared with the former mice ( Figs. 7, B and C ), sug-
gesting that T cell – derived IL-6 controls mucosal infl amma-
tion in oxazolone-induced colitis. 
 DISCUSSION 
 UC is an IBD characterized by chronic relapsing, immuno-
logically mediated infl ammation of the intestine ( 1, 35 ). Here, 
we have identifi ed a central pathogenic role for the transcrip-
tion factor NFATc2 in chronic intestinal infl ammation. In an 
initial series of studies, we demonstrated that NFATc2 ex-
pression is increased in lamina propria T cells in UC compared 
with control patients. We then took advantage of genetically 
altered mice that lack NFATc2 to uncover a critical role 
for this factor in chronic intestinal infl ammation. We found 
that NFATc2 – and IL-6 – defi cient T cells fail to induce T cell –
 mediated oxazolone colitis. In further mechanistic studies, we 
found that NFATc2 defi ciency blocks IL-6 production by mu-
cosal T lymphocytes thereby inducing T cell apoptosis and 
preventing development of IL-6/-13 – producing T cells. Fi-
nally, we showed that activation of IL-6 signaling in vivo 
via hyper-IL-6 abrogates the protective eff ects of NFATc2 
defi ciency in T cell – mediated colitis and induces IL-6 and -13 
production. These data identify NFATc2 as a master regu-
lator for IL-6 production and subsequent T cell activation in 
experimental colitis in vivo. 
 Consistent with a recent proteomic study in UC ( 36 ), we 
observed that expression of NFATc2 proteins is increased in 
IBD patients. The fi nding that lamina propria T lymphocytes 
in patients with IBD expressed increased amounts of NFATc2 
led us to further investigate the functional role of this tran-
scription factor in a T cell – mediated animal model of IBD 
( 33 ). These results demonstrated a potent regulatory role of 
IL-6 – defi cient (B, bottom right) mice upon oxazolone administration. IL-
6 – defi cient mice were signifi cantly (*, P  < 0.05) protected from oxazo-
lone-induced colitis. 
 
However, IL-17F production was also reduced in the absence 
of NFATc2 as compared with WT mice in oxazolone colitis 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20072484/DC1), suggesting that NFATc2 controls Th17 
cytokine production in experimental colitis. 
 In subsequent experiments, we purifi ed lamina propria CD4 + 
T cells from WT and NFATc2-defi cient mice in oxazolone-
induced colitis using immunomagnetic beads, and thereby 
determined IL-6 production. As shown in  Fig. 4 C , NFATc2-
defi cient lamina propria T cells produced signifi cantly less 
IL-6 than WT T cells, suggesting that NFATc2 controls IL-6 
production by mucosal T cells in experimental colitis. Con-
sistently, a lower amount of IL-6 – expressing cells was noted 
in the lamina propria of NFATc2 KO mice compared with 
WT mice in oxazolone colitis (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20072484/DC1). 
 IL-6 and -13, but not the IL-23/IL-17A axis, is required 
for oxazolone-induced colitis 
 To determine the functional role of the aforementioned cy-
tokines in vivo, we next performed studies in oxazolone-
 induced colitis using specifi c KO mice. As shown in Fig. S4 
(A and B, available at http://www.jem.org/cgi/content/full/
jem.20072484/DC1), both IL-23p19 – and IL-17A – defi cient 
mice showed no signifi cant reduction of colitis activity, as 
determined by weight curves, endoscopic scores, and histo-
logical assessment (unpublished data), suggesting that other 
cytokines produced by T cells could play a pathogenic role. 
Interestingly, IL-6 levels produced by IL-17A – and IL-
23p19 – defi cient lamina propria cells were comparable to WT 
cells (Fig. S2). However, mice defi cient for IL-13 ( Fig. 5 A ) 
and IL-6 ( Fig. 5 B ) showed signifi cant protection from oxa-
zolone-induced colitis. These mice showed a reduction of 
weight loss and endoscopic colitis activity compared with 
WT mice. Collectively, these data suggested that IL-6 and -13, 
rather than IL-23 and -17A, play a major pathogenic role in 
oxazolone colitis. 
 IL-6 signaling reverses the protective effect of NFATc2 
defi ciency in experimental colitis 
 The above fi ndings were consistent with the hypothesis that 
the reduced susceptibility of NFATc2-defi cent mice for oxa-
zolone-induced colitis is caused by suppression of IL-6 pro-
duction by mucosal T cells with consecutive T cell apoptosis. 
To test whether activation of IL-6 signaling in vivo could 
overcome the reduced susceptibility of NFATc2-defi cient 
mice to oxazolone-induced colitis, we next treated NFATc2-
defi cient mice upon oxazolone administration with hyper-
IL-6. In these studies, NFATc2-defi cient mice were injected 
i.p. with hyper-IL-6 1 d before intrarectal challenge with oxa-
zolone. Interestingly, NFATc2-defi cient mice given hyper-
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 Figure 6.  Administration of hyper-IL-6 restores the susceptibility of NFATc2-defi cient mice to oxazolone-induced colitis.  (A) Oxazolone coli-
tis was induced by sensitizing mice with oxazolone, followed by intrarectal administration after 7 d and monitoring of the body weight at indicated time 
points. Hyper IL-6 (hIL-6; 1  μ g per mouse) was given i.p. before oxazolone administration. Weight curves from one representative experiment out of three 
are shown. Data represent mean values  ± the SEM. Hyper-IL-6 administration led to colitis development and weight loss in oxazolone-treated NFATc2 KO 
mice, but had little effect on colitis activity in WT mice. This experiment was performed three times with groups of four to fi ve mice. (B) Histological anal-
ysis of colonic infl ammation in WT and NFATc2-defi cient mice given PBS or hyper-IL-6. Signs of infl ammation such as goblet cell depletion, erosions, and 
accumulation of mononuclear cells were noted in NFATc2-defi cient mice treated with hyper-IL-6, but not control-treated NFATc2 KO mice. (C) Quantita-
tive histopathologic assessment of colitis activity showed a signifi cant (P  < 0.05) protection from infl ammation and tissue injury in NFATc2-defi cient mice 
compared with WT mice, whereas no signifi cant difference was noted between WT mice and NFATc2 KO mice given hyper-IL-6. Data represent mean val-
ues  ± the SEM. (D) Endoscopic analysis of the colon of WT and NFATc2-defi cient mice at day 2 after application of oxazolone. Oxazolone-induced erosions 
and ulcers were seen in the WT and NFATc2/hyper-IL-6 groups, whereas a normal colon architecture was noted in NFATc2-defi cient mice. (E) Quantitative 
endoscopic score of infl ammation (MEICS score). A signifi cantly lower endoscopic score was observed in NFATc2-defi cient mice compared with WT mice 
and NFATc2-defi cient mice treated with hyper-IL-6. (F) IL-6 and -13 cytokine production by isolated CD4 + CD25    splenic T cells and LPMCs in oxazolone 
colitis. Whereas NFATc2-defi cient cells produced lower amounts of IL-6 and -13 than WT cells, hyper-IL-6 administration led to a strong induction of IL-6 
and -13 production by cells lacking NFATc2. No changes in IFN-  production were noted between NFATc2 KO mice and NFATc2 KO mice given hIL-6 (not 
depicted). (G) Increased numbers of CD4 + T cells in NFATc2-defi cient mice after administration of hIL-6 in oxazolone colitis. Cryosections of colonic tissue 
were incubated with anti-CD4 antibodies and stained with conjugated Cy3 antibodies. An increased number of CD4 + T cells was observed in colonic tissue 
from WT mice during oxazolone-induced colitis compared with NFATc2 KO mice. After administration of hIL-6, NFATc2-defi cient mice showed increased 
numbers of CD4 + T cells compared with NFATc2 mice without hIL-6 administration. Negative control staining is shown. Bars: (B) 100  μ m; (G) 80  μ m. 
JEM VOL. 205, September 1, 2008 
ARTICLE
2107
 Figure 7.  Adoptive T cell transfer from WT and IL-6 – defi cient 
mice in SCID mice.  (A) CD4 + T cells from WT and IL-6 donor mice were 
transferred into CB-17/SCID mice, followed by oxazolone sensitization 
and intrarectal oxazolone administration. The body weight of reconsti-
tuted mice was analyzed at the indicated time points. Mean values  ± the 
SEM from one representative experiment are shown. Whereas mice re-
constituted with WT T cells showed a marked weight loss, mice given 
IL-6 – defi cient T cells were protected from colitis. For this experiment, 
four SCID mice in each group were used. (B) Endoscopic assessment of 
colonic infl ammation of SCID mice reconstituted with WT (left) or IL-6 –
 defi cient (right) T cells upon oxazolone administration. Endoscopy was 
performed 2 d after intrarectal oxazolone challenge. (C) Quantitative 
endoscopic analysis of infl ammation (MEICS score) of SCID mice in oxa-
zolone colitis was done 2 d after administration of oxazolone. A signifi -
cantly (P  < 0.05) lower endoscopic score was observed in SCID mice 
reconstituted with T cells from IL-6 – defi cient mice as compared with the 
WT group. 
NFATc2 in experimental colitis. In fact, NFATc2 KO mice 
were protected from oxazolone colitis, and this protective 
eff ect could be adoptively transferred by T lymphocytes, 
strongly suggesting that NFATc2 regulates mucosal T cell 
activity in vivo. 
 Previous studies have shown that inactivation of the 
NFATc2 gene leads to increased numbers of peripheral lym-
phocytes ( 23, 27, 29 ). This fi nding is at least partially caused 
by a defect of NFATc2-defi cient splenic T cells to undergo 
activation-induced cell death in a Fas/FasL-dependent path-
way. In contrast to these fi ndings in peripheral T cells, we 
observed a signifi cantly increased number of apoptotic mu-
cosal CD4 + T cells in NFATc2-defi cient mice in experi-
mental colitis, suggesting that augmented T cell death in the 
absence of NFATc2 might contribute to protection from 
experimental colitis. To analyze the potential mechanism for 
these diff erences in mucosal T cell apoptosis, we next assessed 
the production of proinfl ammatory cytokines in experimen-
tal colitis. Consistent with previous studies on augmented 
Th2 T cell development by NFATc2-defi cient T cells ( 27 ), 
we observed that splenic T cells from NFATc2 KO mice 
in oxazolone colitis produced signifi cantly more IL-4 than 
T cells from WT mice. However, no signifi cant diff erences 
in the production of this cytokine were observed between 
WT and NFATc2-defi cient mucosal T cells, whereas IL-5 
production was induced in the absence of NFATc2. In con-
trast, the production of IL-6, -13, and -17 was signifi cantly 
reduced by NFATc2-defi cient mucosal T cells compared 
with control WT T cells. Interestingly, IL-17 production was 
reduced in spite of normal or even increased levels of the 
Th17 master transcription factor ROR  t ( 37 – 39 ), suggesting 
that both ROR  t and NFATc2 are required to induce opti-
mal IL-17 production by a large number of mucosal T cells. 
However, both IL-23 – and IL-17A – defi cient mice showed 
normal susceptibility for oxazolone colitis, suggesting that 
other cytokines might be crucial for the decreased suscepti-
bility of NFATc2-defi cient mice to oxazolone colitis. 
 IL-6 is a multifunctional cytokine with pro- and antiin-
fl ammatory properties ( 40 ), and it stimulates target cells via a 
membrane receptor complex consisting of the IL-6 receptor 
(IL-6R) and the signaling receptor subunit gp130 ( 41 ). 
Although gp130 is ubiquitously expressed, the IL-6R is only 
found on hepatocytes and some hematopoietic cells. Interest-
ingly, a soluble form of the IL-6R (sIL-6R) has been shown 
to bind IL-6 and to stimulate gp130 on cells that do not express 
the IL-6R. This process has been named IL-6 trans-signaling 
( 42 – 44 ) and activates T cells lacking the IL-6R such as most 
mucosal T cells. As IL-6 signaling has been identifi ed as a key 
regulator of T cell apoptosis in experimental colitis ( 45 – 48 ), 
we have focused on the eff ects of IL-6 trans-signaling in 
NFATc2-defi cient mice. It was found that the administration 
of hyper-IL-6, a potent activator of IL-6/sIL-6R signal trans-
duction ( 44, 49 ), completely restores IL-13 production by 
NFATc2-defi cient T cells and abrogates the protective eff ect 
of NFATc2 defi ciency in oxazolone colitis in vivo. These 
data suggest that NFATc2 regulates experimental colitis in vivo 
in an IL-6 – dependent fashion and that IL-6 signaling is 
important to augment mucosal IL-6 and -13 production. 
Finally, adoptive transfer studies showed that IL-6 produc-
tion by T lymphocytes is important for activity of oxazolone-
induced colitis. 
 NFATc2 defi ciency in RAG KO mice results in the develop-
ment of severe colitis ( 50 ), suggesting that this transcription 
2108 NFACTC2 IN COLITIS | Weigmann et al. 
in 100  μ l 1X PBS 1 d before sensitization and challenge with oxazolone. 
Control mice were injected with PBS at the same time point. In some ex-
periments, splenic CD4 + T cells (5  × 10 6 ) from WT, NFATc2-defi cient, or 
IL-6 – defi cient mice were isolated and injected into syngenic SCID mice, 
followed by sensitization with oxazolone. At day 7 after T cell transfer, 
SCID mice were challenge intrarectally with oxazolone and the body weight 
was monitored at indicated time points. 
 In vivo high resolution miniendoscopic analysis of the colon.  For 
monitoring of colitis activity, a high resolution video endoscopic system 
(Karl Storz) for mice was used ( 53 ). Prominent endoscopic signs of infl am-
mation in CB-17/SCID mice were abrogation of the normal vascular pat-
tern, the presence of mucosal granularity, and the appearance of ulcers. To 
determine colitis activity in reconstituted CB-17/SCID-defi cient mice or 
hapten-treated mice the mice were monitored by miniendoscopy at indi-
cated time points, and endoscopic scoring of fi ve parameters (translucent, 
granularity, fi brin, vascularity, and stool) was performed. 
 Isolation of LPMCs.  LPMCs were isolated from freshly obtained colonic 
specimens using a modifi cation of previously described techniques ( 54 – 56 ). 
LPMCs were collected at the interphase of the Percoll gradient, washed 
once, and resuspended in FACS buff er or cell culture medium. For some 
experiments, CD4 + T cells were isolated from LPMC preparations by using 
anti-CD4 antibodies conjugated with microbeads (Miltenyi Biotec) accord-
ing to the manufacturer ’ s instructions. 
 Preparation of cytospins.  Lamina propria cells were isolated and resuspended 
in PBS/1% FCS at a density of 10 6 cells/ml in PBS. Slides were prepared in a 
Cytospin2-centrifuge (Shandon) and loaded with 200  μ l cell suspension. After 
centrifugation at 500 upm for 5 min, slides were removed and dried for 2 h. 
Slides were subsequently stained using specifi c anti-bcl-xl and anti-bcl-2 anti-
bodies, as specifi ed above. Samples were analyzed by microscopy. 
 T cell culture and cytokine assays.  To measure cytokine production, 10 6 
splenic T cells per ml were activated with 10  μ g/ml purifi ed hamster anti –
 mouse CD3  (clone 145-2C11) and 5  μ g/ml soluble hamster anti – mouse 
CD28 (clone 37.51) and cultured in complete medium or serum-free me-
dium. LPMCs were stimulated with PMA/ionomycin or anti-CD3/CD28 
antibodies. Cytokine concentrations were determined by using commer-
cially available mouse FlowCytomix systems (Bender MedSystems). For 
measurement of IL-6, -13, and -17F levels, commercially available ELISA 
kits (R & D Systems and Bender MedSystems) were used. 
 Histological analysis of colon cross sections.  Colon samples were re-
moved from colitic mice at indicated points of time. 4  μ m paraffi  n sections 
were made and stained with hematoxylin and eosin. For colitis induced by 
oxazolone, the degree of infl ammation and epithelial injury on microscopic 
cross sections of the colon was graded semiquantitatively from 0 to 6 ( 18 ). 
Grading of colitis activity was done in a blinded fashion by the same patholo-
gist (H.A. Lehr). Small bowel sections were taken from the same animals as 
an additional control and showed no evidence of infl ammation. 
 FACS analysis.  For FACS analysis, apoptotic cells were detected by stain-
ing with Annexin V antibodies, and necrotic cells were stained with 7-AAD 
and the cells were analyzed using a FACSCalibur (BD Biosciences). 
 Analysis of cell apoptosis in colonic specimens.  To visualize apoptotic 
cells, cryosections of colonic tissue were analyzed by TUNEL assay using a 
commercially available kit (Oncor-Appligene) according to the manufactur-
er ’ s instructions. Nuclear staining was done with DAPI. For detection of 
CD3 + TUNEL + (double-positive) cells, immunohistochemical studies were 
done after TUNEL staining. Blocking was done by treatment of samples 
with immunoblock kit (Roth) before incubation with a monoclonal anti-
body against CD3 (BD Biosciences). Detection was achieved using a Cy3-
conjugated secondary antibody against mouse IgG (Dianova). 
factor plays a protective role in innate mucosal immune re-
sponses. In contrast, we observed here that NFATc2 plays an 
important pathogenic role in controlling T cell eff ector re-
sponses in experimental colitis. In fact, this study identifi es 
NFATc2 as a master regulator for T cell-mediated oxazolone 
colitis and the regulation of IL-6 production by mucosal 
T cells with subsequent eff ects on T cell cytokine production 
and apoptosis. Thus, modulation of NFATc2 function in 
T cells appears to be an attractive target for therapeutic inter-
vention in T cell – mediated chronic intestinal infl ammation 
such as is observed in IBDs. 
 MATERIALS AND METHODS 
 Patients.  Gut specimens obtained from patients with CD or UC or from 
control patients were studied. Collection of surgical samples was approved 
by the ethical commitee and the institutional review board of the University 
of Mainz. 
 Immunohistochemistry.  Immunohistochemistry was performed on 7- μ m 
cryosections from gut specimens of control and IBD patients, as previously 
described ( 18 ). For staining of NFATc2 transcription factor, the mouse anti-
bodies G1-D10 or G-20 (Santa Cruz Biotechnology) were used. Immuno-
fl uorescence was performed using the tyramide signal amplifi cation Cy3 
system (PerkinElmer). Accordingly, tissues were fi xed in 4% paraformalde-
hyde/PBS, followed by sequential incubation with avidin/biotin- (Vector 
Laboratories), peroxidase-, and protein-blocking reagent (Dako) to elimi-
nate unspecifi c background staining. Sections were incubated with primary 
antibodies specifi c for human CD3 (Dianova) or NFATc2 proteins (Santa 
Cruz Biotechnology), dissolved in PBS/0.5% BSA/0.2% saponin. Sections 
incubated with isotype matched control antibodies served as negative 
control. Next, samples were incubated with biotinylated goat anti – rabbit 
secondary IgG antibody or fl uorescence-conjugated antibody (Dianova) fol-
lowed by incubation with streptavidin-conjugated Cy3 (Dianova) or with 
streptavidin-HRP and stained with tyramide-Cy3, according to the manu-
facturer ’ s instructions. For confocal microscopy (Leitz Microscope) before 
examination, the nuclei were counterstained with DAPI (Vector Labora-
tories), mounted, and analyzed. NFATc2-positive cells in 6 – 10 high power 
fi elds were subsequently counted in all patients per condition. 
 For immunostaining of CD4 + T cells in the lamina propria, a rat anti –
 mouse CD4 (BD Biosciences) antibody was used. Biotinylated goat anti – 
rat antibodies (Dianova) and Streptavidin-Cy3 were used for subsequent 
analysis, as well as counterstaining with DAPI. For immunostaining of anti-
apoptotic proteins, rabbit-anti-bcl-xl (Cell Signaling Technology) and 
Armenian hamster anti-bcl-2 (BD Biosciences) antibodies were chosen. 
Anti – rabbit or anti – Armenian hamster biotinylated antibodies were used for 
subsequent staining in combination with streptavidin-HRP and tyramide-
Cy3 signal amplifi cation. 
 Animals.  2-4-mo-old BALB/c mice were obtained from the central breed-
ing facility at the University of Mainz or from Charles River Laboratories; 
NFATc2-defi cient mice have been described elsewhere ( 27 ). NFATc2-de-
fi cient mice used in the experimental studies were between 4 and 12 wk of 
age. CB-17/SCID mice were obtained from M & B. IL-6 – and IL-13 – defi -
cient mice were previously described ( 51, 52 ). IL-23p19 – and IL-17A – defi -
cient mice were obtained from Regeneron Pharmaceuticals. All animal 
studies were kept in specifi c pathogen – free conditions and approved by the 
Institutional Animal Care and Use Committee of the University of Mainz. 
 Oxazolone-induced colitis.  Oxazolone-induced colitis in BALB/c mice 
was induced using a previously described method ( 18 ). After 2 d, the mice 
were analyzed by miniendoscopy to monitor the manifestation of colitis. 
 For the analysis of hyper-IL-6 (IL-6/sIL-6R fusion protein [ 49 ]) func-
tions, mice were injected i.p. with 1  μ g hyper-IL-6 (per 20 g mice weight) 
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